Technical guide

Liposomal ingredient testing: CoA, HPLC, DLS and TEM

A single test result cannot complete the quality assessment of a liposomal ingredient. Active identity and content, carrier structure and behaviour over time are different questions. A useful dossier addresses each question with an appropriate method and makes clear how the tested research sample relates to the batch being purchased.

Which method answers which question?

Document or methodInformation providedWhat it does not establish alone
CoA / certificate of analysisReported test results for a particular batchThat every batch has received the same detailed characterisation
Chromatography such as HPLCActive identity, amount or related impurities with a suitable methodPresence of liposomal structure
DLSHydrodynamic size and distribution information under the test conditionsMicroscopic carrier morphology
TEM / suitable microscopyImages informing structure and morphology in the prepared sampleHuman absorption or clinical outcomes
Encapsulation assessmentMethod-dependent distinction between free and carrier-associated activeAn automatic finished-product shelf life

Source: FDA (2018) — Liposome Drug Products; analytical assessment framework; NCI — NCL characterisation methods; NIST SP 1200-6 (2015) — Particle size measurement by DLS

Read size data with the test conditions

DLS reports a hydrodynamic measurement. Sample preparation, measurement medium, temperature and analysis approach influence interpretation. A microscopy-derived size should not necessarily be expected to match the DLS result exactly.

PDI provides information about distribution breadth. Rather than applying one PDI limit to every active and product form, review the method and the manufacturer’s justified specification. A useful report identifies the sample and how it was measured, not merely the final number.

Source: NIST SP 1200-6 (2015) — Particle size measurement by DLS; NCI — NCL characterisation methods

Active content and encapsulation are different measurements

Total active content is different from the amount reported as incorporated in the carrier. Encapsulation data should explain the separation method, calculation basis and sample-preparation conditions. Structural disruption during testing or incomplete separation can affect the result.

The basis of the active amount also needs clarification: total ingredient weight, dry matter, a specified compound or elemental content. The serving calculation should use that definition consistently.

Source: FDA (2018) — Liposome Drug Products; analytical assessment framework

Connect batch documentation with the technical file

When assessing a sample or quotation with Biontera, matching document identity is as important as matching the product name and code. It helps preserve traceability between the dossier reviewed by formulation teams and the ingredient ordered by procurement.

  • Manufacturer, product code, batch number and document date.
  • Test method, units, acceptance range and reported result.
  • Whether characterisation relates to the supplied batch or a representative development batch.
  • Microbiological quality and other product-appropriate quality parameters.
  • Storage conditions and retest or expiry date.

How the references are used

The FDA guidance for liposomal drug products and NCI methods are used here to explain analytical assessment topics. They do not establish FDA approval of Biontera ingredients or a universal testing list for all food supplements. The appropriate assessment is determined from the product and its technical dossier.

Source: FDA (2018) — Liposome Drug Products; analytical assessment framework; NCI — NCL characterisation methods

Common questions

Does an HPLC result prove that an ingredient is liposomal?

A suitable HPLC method can address questions such as active identity and amount. Carrier structure requires additional appropriate characterisation evidence.

Does a TEM image replace a human study?

TEM provides structural information. Absorption and clinical outcomes require different research; these evidence types are not interchangeable.

Must every CoA include TEM and DLS?

The testing programme depends on product characteristics and the quality approach. Some characterisation data may appear in separate technical reports; their relationship to the batch document should be explained.

Explore the portfolio

From understanding to selection.

Let’s assess your next formulation.

Share your dosage form, intended amount per serving and estimated annual requirement. We can plan ingredient selection, technical documentation and sample evaluation together.

Discuss documents and samples